Cyberonics comes under SEC (Securities and Exchange Commission) spotlight in US
This article was originally published in Clinica
Cyberonics has joined the growing list of companies whose stock options programme are being investigated by the US Securities and Exchange Commission (SEC) for potential backdating of option grants to benefit the recipients.
You may also be interested in...
Tensions between industry and the European Commission on the issue of health claims for botanical food supplements were aired on the second day of the BAH's High Level Conference on the Future of Medicines, with the EC saying the EU Green Deal is now higher up on its list of priorities for the foreseeable future.
Issues over supply and the use of a skinny label have the potential to take a toll on the market for the fish oil drug icosapent ethyl, one analyst has claimed in the wake of Hikma’s recent generic launch.
The German Bundestag has adopted the Unified Patent Court’s draft ratification bill with the necessary qualified majority.